ContributorsPublishersAdvertisers

Acalabrutinib Shows Higher Tolerability Versus Ibrutinib in CLL

targetedonc.com
 2021-12-02

Cover picture for the articleJohn C. Byrd, MD, discusses the early results and adverse events observed in the ELEVATE-RR trial in patients with chronic lymphocytic leukemia. John C. Byrd, MD, professor and chair of the University of Cincinnati College of Medicine Department of Internal Medicine, the D. Warren Brown Chair of Leukemia Research, and Distinguished...

www.targetedonc.com

Comments / 0

Comments / 0